0 XP 0   0   0  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Akero Therapeutics Inc - Trending symbols

Latest News of Akero Therapeutics Inc

DateTitleRead
2025-10-10
04:32
Akero Therapeutics (AKRO) Jumps 16% on $5.2-Billion Novo Nordisk MergerRead
2025-10-10
00:19
Stocks Falter as Higher Bond Yields Spark Long LiquidationRead
2025-10-09
22:34
Stocks Falter as Higher Bond Yields Spark Long LiquidationRead
2025-10-09
21:26
Noteworthy Thursday Option Activity: AKRO, DHI, AFRMRead
2025-10-09
19:12
Stocks Fall on Higher Bond Yields and Weakness in ChipmakersRead
2025-09-26
16:32
LLY Gets EU Approval for Alzheimer's Drug & FDA Nod to Cancer TherapyRead
2025-09-19
18:24
NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock UpRead
2025-09-19
17:47
YieldBoost DTE To 11.5% Using OptionsRead
2025-09-18
22:15
AKERO THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Akero Therapeutics, Inc. - AKRORead
2025-09-16
18:54
Krystal Biotech Stock Up on FDA Nod to Vyjuvek Label UpdateRead

Notifications

TypeNotificationDate
RSI OverboughtOverbought RSI (Relative Strength Index)2025-10-10



Trends

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Gross Profit -65-3-68-1-6964-5287282
Net Interest Income -362-95-457-400-857-31-88824,20123,313
Income Tax Expense -191-358-549-2,025-2,574109-2,4658,7256,260
Cost of Revenue 15,12813,83828,966-4,61324,3538,08632,439-58,490-26,051

Comments

How you think about this?

Leave a comment

Stay informed about Akero Therapeutics Inc.

Receive notifications about Akero Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.